Ser A · CUSIP 786700104 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of Sagimet Biosciences Inc. (Nasdaq: SGMT) on Form 13F for 30 June 2026. Between them they reported USD 78m. The largest position belongs to Balyasny Asset Management, at USD 28m. The manager with the most riding on it is Great Point Partners, where it is 3.0% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Balyasny Asset Management25 funds on PPLI.com | USD 28m | 0.0% |
| 2 | Great Point Partners2 funds on PPLI.com | USD 16m | 3.0% |
| 3 | Baker Bros. Advisors2 funds on PPLI.com | USD 7.4m | 0.0% |
| 4 | Millennium Management6 funds on PPLI.com | USD 7.2m | 0.0% |
| 5 | Boothbay Fund Management2 funds on PPLI.com | USD 3.6m | 0.0% |
| 6 | Farallon Capital Management56 funds on PPLI.com | USD 3.2m | 0.0% |
| 7 | Renaissance Technologies13 funds on PPLI.com | USD 2.7m | 0.0% |
| 8 | Atom Investors1 fund on PPLI.com | USD 2.7m | 0.2% |
| 9 | Palo Alto Investors6 funds on PPLI.com | USD 1.9m | 0.3% |
| 10 | Rock Springs Capital Management2 funds on PPLI.com | USD 1.9m | 0.1% |
| 11 | Sofinnova Investments1 fund on PPLI.com | USD 1.3m | 0.1% |
| 12 | Citadel Advisors32 funds on PPLI.com | USD 809,000 | 0.0% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 633,000 | 0.0% |
| 14 | Awm Investment Company6 funds on PPLI.com | USD 618,000 | 0.1% |
| 15 | Hudson Bay Capital Management8 funds on PPLI.com | USD 385,000 | 0.0% |
| 16 | D. E. Shaw & Co.15 funds on PPLI.com | USD 171,000 | 0.0% |
| 17 | Persistent Asset Partners10 funds on PPLI.com | USD 80,152 | 0.0% |
| 18 | The Quarry1 fund on PPLI.com | USD 989 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Great Point Partners | USD 16m | 3.0% |
| 2 | Palo Alto Investors | USD 1.9m | 0.3% |
| 3 | Atom Investors | USD 2.7m | 0.2% |
| 4 | Rock Springs Capital Management | USD 1.9m | 0.1% |
| 5 | Sofinnova Investments | USD 1.3m | 0.1% |
| 6 | Awm Investment Company | USD 618,000 | 0.1% |
| 7 | Boothbay Fund Management | USD 3.6m | 0.0% |
| 8 | Baker Bros. Advisors | USD 7.4m | 0.0% |
| 9 | Balyasny Asset Management | USD 28m | 0.0% |
| 10 | Persistent Asset Partners | USD 80,152 | 0.0% |
Sagimet Biosciences Inc. trades under the symbol SGMT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 786700104.
18 of the 720 hedge fund managers PPLI.com tracks reported Sagimet Biosciences Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Balyasny Asset Management (USD 28m), Great Point Partners (USD 16m), Baker Bros. Advisors (USD 7.4m), Millennium Management (USD 7.2m) and Boothbay Fund Management (USD 3.6m).
18 managers in our coverage reported it, and between them they run 223 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Great Point Partners, where the position was 3.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Sagimet Biosciences Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.